Philogen S.p.A. announced that Pfizer Inc. (NYSE: PFE) has exercised options granted under the agreement established in December 2014 for the potential development and commercialization of multiple antibody drug conjugates (ADCs). Siena, Italy, 21st January 2016.
Press Release
- Published